A roadmap to key pharmacologic principles in using antipsychotics

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 9, Issue 6, 2007, Pages 444-454

  Culpepper, Larry ^a,b,c,d  

^a Forest   (United States)

^b Eli Lilly ^*

^c International Affairs at Pfizer

^d Neurocrine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; BLOOD BRAIN BARRIER; BODY MASS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; EXTRAPYRAMIDAL SYNDROME; GENETIC VARIABILITY; HUMAN; HYPERPROLACTINEMIA; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 37249022281     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v09n0607     Document Type: Review

References (32)

1. Weiden PJ, Preskorn SH, Fahnestock PA, et al. Translating the Psychopharmacology of Antipsychotics to Individualized Treatment for Severe Mental Illness: A Roadmap. J Clin Psychiatry 2007;68 (suppl 7):1-48
2. Preskorn SH, Flockhart DA. 2006 Guide to Psychiatric Drug Interactions. Prim Psychiatry 2006;13:35-64
3. Levy RH, Thummel KE, Trager WF, et al. Metabolic Drug Interactions. Philadelphia, Pa: Lippincott, Williams & Wilkins; 2000
4. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions (pt 1). J Psychiatr Pract 2003;9:376-384
5. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions (pt 2). J Psychiatr Pract 2004;10:177-181
6. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172:1703-1716
7. Preskorn SH. The slippery slide. J Pract Psychiatry Behav Health 1999;5:50-55
8. Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clinic Proc 1994;69:1069-1081
9. Abilify [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2006
10. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? a review of the evidence. Neuropsychopharmacology 1998;18:63-101
11. Bymaster FP, Hemrick-Luecke SK, Perry KW, et al. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl) 1996;124(1-2):87-94
12. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-113
13. Nyberg S, Farde L, Halldin C. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy: a PET study in haloperidol-treated patients. Psychiatry Res 1996;67:163-171
14. Preskorn SH. Defining "is." J Pract Psychiatry Behav Health 1999;5:224-228
15. Medication-induced movement disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:734-736
16. Weiden PJ. Switching in the era of atypical antipsychotics: an updated review. Postgrad Med 2006 Sept; Spec No: 27-44
17. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27
18. Frankle WG, Gil R, Hackett E, et al. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl) 2004;175(4): 473-480
19. A body mass index calculator. National Institutes of Health Heart, Lung, and Blood Institute Web site. Available at: http://www.nhlbisupport.com/bmi
20. US Preventive Services Task Force (USPSTF), Agency for Healthcare Research and Quality Web site. Available at: http://www.ahrq.gov/clinic/ uspstfix.htm
21. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. J Clin Psychiatry 2007; 68(suppl 6):14-23
22. Newcomer JW. Second-Generation (atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review. CNS Drugs 2005;19(suppl 1):1-93
23. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry 2004;65(2):267-272
24. Dixon L, Lucksted A, Stewart B, et al. Outcomes of the peer-taught 12-week family-to-family education program for severe mental illness. Acta Psychiatr Scand 2004;109:207-215
25. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610
26. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91
27. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001;22:724-763
28. El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia: systematic review. Br J Psychiatry 2006;189:102-108
29. Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry 2004;161(suppl 2):1-56
30. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
31. Ziedonis DM. Integrated treatment of co-occurring mental illness and addiction: clinical intervention, program, and system perspectives. CNS Spectrums 2004;9:892-904, 925
32. Ziedonis DM, Smelson D, Rosenthal RN, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11:315-339